India's version of AstraZeneca's coronavirus vaccine is not authorised in the EU due to the possibility of “differences” with the original, Europe's drug regulator has said.

The African Union has complained that the EU's non-recognition of the low-cost Indian-made Covishield jab might be detrimental to people in Africa where it is widely used.

“Even though it may use an analogous production technology to Vaxzevria (AstraZeneca's vaccine), Covishield as such is not currently approved under EU rules,” the European Medicines Agency (EMA) said in a statement to AFP.

“This is because vaccines are biological products. Even tiny differences in the manufacturing conditions can result in differences in the final product, and EU law therefore requires the manufacturing sites and production process to be assessed and approved as part of the authorisation process.”

Opinion

Editorial

Sustainable path?
13 Jun, 2026

Sustainable path?

THE FY27 budget is the first clear signal that the government is ready to transition from stabilisation to growth ...
Prioritising education
13 Jun, 2026

Prioritising education

THOUGH the improvement in the country’s literacy rate may be slight, as highlighted by the Economic Survey, it ...
Poverty’s rise
13 Jun, 2026

Poverty’s rise

AS attention turns to the government’s plans for the coming fiscal year, one set of figures deserves particular...
A difficult story
Updated 12 Jun, 2026

A difficult story

Unless productivity becomes the dominant target of economic policy, Pakistan will continue to oscillate between crises and fragile recovery.
Rough waters
12 Jun, 2026

Rough waters

AMONGST the key potential triggers for fresh conflict in South Asia is water. The Indian state is behaving in an...
Politicised football
12 Jun, 2026

Politicised football

ALMOST three-and-half years since Lionel Messi led Argentina to FIFA World Cup glory, the latest edition of...